17,266 Shares of Caris Life Sciences, Inc. $CAI Acquired by NorthCrest Asset Manangement LLC

NorthCrest Asset Manangement LLC acquired a new position in shares of Caris Life Sciences, Inc. (NASDAQ:CAI) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 17,266 shares of the company’s stock, valued at approximately $529,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in CAI. Braidwell LP boosted its holdings in shares of Caris Life Sciences by 3.1% in the 2nd quarter. Braidwell LP now owns 8,256,032 shares of the company’s stock worth $147,122,000 after purchasing an additional 246,585 shares during the period. PointState Capital LP purchased a new stake in Caris Life Sciences during the 2nd quarter valued at $121,690,000. BlackRock Inc. bought a new stake in Caris Life Sciences in the second quarter worth $98,666,000. Canada Pension Plan Investment Board purchased a new position in Caris Life Sciences during the second quarter worth $24,502,000. Finally, Amundi boosted its stake in Caris Life Sciences by 5,709.5% during the second quarter. Amundi now owns 1,218,364 shares of the company’s stock worth $21,711,000 after buying an additional 1,197,392 shares during the period.

Insider Activity

In other Caris Life Sciences news, President David Spetzler sold 478,000 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $24.86, for a total transaction of $11,883,080.00. Following the transaction, the president owned 1,052,083 shares in the company, valued at approximately $26,154,783.38. This represents a 31.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Brian Brille sold 400,000 shares of the company’s stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $30.33, for a total value of $12,132,000.00. Following the completion of the transaction, the insider directly owned 230,303 shares in the company, valued at approximately $6,985,089.99. The trade was a 63.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,004,712 shares of company stock worth $27,205,419 over the last 90 days. 50.00% of the stock is currently owned by corporate insiders.

Caris Life Sciences Stock Down 3.8%

Shares of NASDAQ:CAI traded down $1.20 during trading hours on Friday, hitting $30.56. The company’s stock had a trading volume of 2,730,080 shares, compared to its average volume of 4,909,658. The firm’s fifty day moving average price is $27.12 and its 200 day moving average price is $20.92. The company has a debt-to-equity ratio of 0.66, a current ratio of 5.53 and a quick ratio of 4.88. The company has a market capitalization of $8.64 billion, a price-to-earnings ratio of 84.89 and a beta of 0.86. Caris Life Sciences, Inc. has a 52 week low of $14.19 and a 52 week high of $33.13.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on CAI. Weiss Ratings lowered shares of Caris Life Sciences from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, October 2nd. Wall Street Zen raised shares of Caris Life Sciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. Evercore reiterated an “outperform” rating and set a $26.00 price target on shares of Caris Life Sciences in a report on Thursday, August 6th. UBS Group began coverage on shares of Caris Life Sciences in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $28.00 price objective on the stock. Finally, TD Cowen increased their price target on Caris Life Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday. Eight equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Caris Life Sciences has an average rating of “Moderate Buy” and a consensus target price of $27.82.

Caris Life Sciences Profile

Caris Life Sciences is a biotechnology company focused on precision oncology and the use of molecular and artificial intelligence technologies to support cancer diagnosis and treatment decisions. The company analyzes tumor and blood samples to identify genetic, molecular and other biological characteristics that may help physicians select targeted therapies and develop individualized treatment plans.

Its offerings include comprehensive tumor profiling, molecular testing and data-driven clinical support for oncologists and other healthcare providers.